A new trading day began on Monday, with BioXcel Therapeutics Inc (NASDAQ: BTAI) stock price up 6.28% from the previous day of trading, before settling in for the closing price of $2.07. BTAI’s price has ranged from $1.17 to $9.26 over the past 52 weeks.
During the last 5-year period, the sales growth of Healthcare Sector giant was 6.20%. Meanwhile, its annual earnings per share averaged 72.31%. With a float of $21.02 million, this company’s outstanding shares have now reached $21.87 million.
BioXcel Therapeutics Inc (BTAI) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of BioXcel Therapeutics Inc is 3.89%, while institutional ownership is 10.78%. The most recent insider transaction that took place on Dec 16 ’24, was worth 58. In this transaction an insider of this company sold 165 shares at a rate of $0.35, taking the stock ownership to the 19,957 shares. Before that another transaction happened on Dec 16 ’24, when Company’s CEO and President sold 3,117 for $0.36, making the entire transaction worth $1,131. This insider now owns 59,605 shares in total.
BioXcel Therapeutics Inc (BTAI) Recent Fiscal highlights
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -3.56 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.72 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 72.31% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 55.37% during the next five years compared to 6.20% growth over the previous five years of trading.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Trading Performance Indicators
Here are BioXcel Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.16. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 64.15.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -9.70, a number that is poised to hit -0.84 in the next quarter and is forecasted to reach -3.04 in one year’s time.
Technical Analysis of BioXcel Therapeutics Inc (BTAI)
Looking closely at BioXcel Therapeutics Inc (NASDAQ: BTAI), its last 5-days average volume was 0.46 million, which is a drop from its year-to-date volume of 4.08 million. As of the previous 9 days, the stock’s Stochastic %D was 61.46%.
During the past 100 days, BioXcel Therapeutics Inc’s (BTAI) raw stochastic average was set at 13.27%, which indicates a significant decrease from 78.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.17 in the past 14 days, which was lower than the 0.40 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.16, while its 200-day Moving Average is $2.35. However, in the short run, BioXcel Therapeutics Inc’s stock first resistance to watch stands at $2.29. Second resistance stands at $2.39. The third major resistance level sits at $2.50. If the price goes on to break the first support level at $2.09, it is likely to go to the next support level at $1.98. Now, if the price goes above the second support level, the third support stands at $1.88.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Key Stats
With a market capitalization of 48.11 million, the company has a total of 21,869K Shares Outstanding. Currently, annual sales are 2,270 K while annual income is -59,600 K. The company’s previous quarter sales were 100 K while its latest quarter income was -30,910 K.
